Propylene Glycol vs Butylated Hydroxyanisole: which is worse?

What is Propylene Glycol?

Propylene glycol is a synthetic organic compound used as a humectant, solvent, and emulsifier in food, pharmaceuticals, cosmetics, and industrial applications. It is produced from propylene oxide (derived from petroleum). Its chemical formula is C3H8O2.

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.

Documented risks

Propylene Glycol: Propylene glycol is generally considered safe by the FDA and is metabolized by the liver to lactic acid and pyruvate (normal metabolites). However, at high doses — particularly from intravenous pharmaceutical formulations — propylene glycol can accumulate and cause lactic acidosis, kidney toxicity, and CNS effects. These effects are seen in critically ill patients receiving high-dose PG-containing intravenous medications, not from food consumption. In children and people with impaired liver or kidney function, PG accumulation may occur at lower doses than in healthy adults. Animal studies have found reproductive and developmental effects at high doses. EFSA's 2018 re-evaluation found no concerns at typical food use levels but noted the EU limits PG use as a direct food additive, using it only as a carrier solvent for permitted additives.

Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.